Does Dr. RENCHELL ANDRES have financial conflicts of interest?

Dr. RENCHELL ANDRES (MD) has received a total of $1,075 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,075 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. RENCHELL ANDRES?

According to CMS Open Payments data, Dr. RENCHELL ANDRES received funding from SALIX PHARMACEUTICALS, A DIVISION OF BAUSCH HEALTH US ($165), TAKEDA PHARMACEUTICALS U.S.A ($157), and GENZYME CORPORATION ($137).

Does Dr. RENCHELL ANDRES receive research grants or speaking fees?

Dr. RENCHELL ANDRES has received $1,075 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. RENCHELL ANDRES

MDReal-Time Hydrated

Specialty: Anesthesiology

Practice Location: LAS VEGAS, NV 89113

NPI Number: 1386815199

LIFETIME INDUSTRY VALUE

$1,075

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. ANDRES is a verified Anesthesiology practitioner based in LAS VEGAS, NV.

Between 2021 and 2025, Dr. ANDRES had an overall industry promotional and research financial footprint of $1,075 as recorded in the federal CMS Open Payments database.

$1,075 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ANDRES's primary funding source is SALIX PHARMACEUTICALS, A DIVISION OF BAUSCH HEALTH US, which accounts for $165 (representing 15.3% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

SALIX PHARMACEUTICALS, A DIVISION OF BAUSCH HEALTH US

Rank 1

$165

15.3%

TAKEDA PHARMACEUTICALS U.S.A

Rank 2

$157

14.6%

GENZYME CORPORATION

Rank 3

$137

12.8%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.